Harlem Prevention Center

ICAP’s two research centers in New York, the Bronx Prevention Center and the Harlem Prevention Center, are hubs of research in New York City that have been historically underserved and disproportionately impacted by the HIV epidemic and, more recently, the COVID-19 epidemic. ICAP works with local community-based organizations, religious leaders, and advocates to promote community awareness of, and engagement with the research studies.

The Community Advisory Board (CAB) for the ICAP Clinical Trials Unit (CTU) provides guidance and feedback on proposed studies, outreach strategies, feedback on study materials, and information regarding community perceptions of the potential or current research studies.

Current studies include investigations of antibody-mediated prevention using broadly neutralizing antibodies (bnAbs) to prevent HIV or COVID-19, an injectable long-acting pre-exposure prophylaxis (PrEP) option, mobile technologies to improve PrEP adherence, integrated care for people who inject opiates, HIV vaccine studies, and studies of COVID-19 immunity, vaccine efficacy, and treatment among others.


ACTG 5418 STOMP Study

  • current
A randomized, placebo-controlled, double-blinded trial of the safety and efficacy of tecovirimat for the treatment of human monkeypox virus disease. https://actgnetwork.org/studies/a5418-study-of-tecovirimat-for-human-monkeypox-virus-stomp/; https://www.stomptpoxx.org/main ...

DMID 19-0004 (The MAGI Study)

  • current
A Phase II randomized, observer-blind, placebo-controlled study to assess the efficacy of meningococcal Group B vaccine rMenB+OMV NZ (Bexsero) in preventing gonococcal infection Link(s): https://clinicaltrials.gov/ct2/show/NCT04350138 ...

HPTN 091: I AM Study

  • current
HPTN 091 is a study assessing the feasibility, acceptability, preliminary impact of a multi-component strategy that provides HIV prevention services, gender-affirming hormone therapy, and Peer Health Navigation to improve pre-exposure prophylaxis (PrEP) uptake and adherence. Web Links: https://www.hptn.org/research/studies/hptn091 ...

HTPN 083: Give PrEP a Shot

  • current
HPTN 083 recruited HIV-uninfected men who have sex with men and transgender women at risk for acquiring HIV infection to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for PrEP and demonstrated the superiority of cabotegravir for HIV prevention in these populations.Closed to enrollment, in active study follow-up Web Links: https://clinicaltrials.gov/ct2/show/NCT02720094  https://www.hptn.org/research/studies/hptn083  ...

ICAP in Harlem

Active Years

2009 to Present

Key Technical Areas
  • Clinical Research and Trials
  • COVID-19 Research
  • PreP Research
  • Surveys
Current Funders
  • National Institute of Health
  • National Institute of Allergy and Infectious Diseases (NIH/NIAID)
  • Department of Health and Human Services (DHHS)
  • Family Health International (FHI)
  • Fred Hutchinson Cancer Research Center
  • Janssen



Site Leader

Yael Hirsch-Moverman, PhD, MPH

Dr. Hirsch-Moverman is an epidemiologist with over 20 years of experience in epidemiologic and implementation research in TB and HIV. Her deep immersion in TB and HIV prevention and treatment research began in New York City, investigating and comparing different approaches to increase adherence to medications among underserved populations. Ultimately, her focus broadened to Africa, where an explosion of TB cases has overlapped with the HIV epidemic.

Dr. Hirsch-Moverman’s work has spanned biomedical domains, including epidemiology and clinical trials, and behavioral domains, including psychosocial issues such as adherence. She is currently focused on designing, conducting, and analyzing the effectiveness and acceptability of interventions to improve patient-centered care in TB and HIV programs in resource-limited settings where TB/HIV infection rates are high. She supports and leads several implementation science research studies that focus on developing evidence-based novel approaches for TB prevention among children in resource-limited settings.

Another aspect of her work focuses on the prevention of HIV in vulnerable populations in the US, namely men who have sex with men (MSM) and transgender women (TGW). She is based at the Harlem Prevention Center Clinical Research Site (CRS), which NIAID funds to conduct HIV prevention and COVID-19 prevention research studies. In addition, the center conducts investigator-initiated research studies examining interventions that increase access to HIV testing and pre-exposure prophylaxis among MSM and TGW.

Jobs in the United States

See the ICAP careers page to search all job listings.